Barclays says the approval of Udenyca OBI adds the 2024 growth outlook of Coherus Biosciences. The approval makes Coherus the only company with all three forms of pegfilgrastim on market, the analyst tells investors in a research note. The firm believes that with Udenyca OBI targeting Neulasta Onpro’s 42% share, the market dynamic for Udenyca looks set to improve in fiscal 2024, “which takes the company one step closer to becoming cash flow positive.” It keeps an Overweight rating on the shares with a $7 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CHRS:
- Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
- Coherus BioSciences Announces New Employment Inducement Grants
- Coherus Biosciences announces updated NCCN practice guidelines for LOQTORZI
- Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
- Coherus BioSciences Announces CFO Transition Plans